Maurits E L Arbouw
Overview
Explore the profile of Maurits E L Arbouw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hulskotte L, Wilbrink-Pijffers I, Arbouw M, Benoist G, Jansman F, van Berlo-van de Laar I
Biomed Chromatogr
. 2024 Apr;
38(7):e5874.
PMID: 38587098
A sensitive and reliable LC-MS/MS method was developed and validated for the quantification of oxycodone and metabolites in human plasma. The method has a runtime of 6 min and a...
2.
Cloesmeijer M, van den Oever H, Mathot R, Zeeman M, Kruisdijk-Gerritsen A, Bles C, et al.
Br J Clin Pharmacol
. 2020 Mar;
86(8):1620-1631.
PMID: 32150285
Aims: The aim of this study was to investigate the population pharmacokinetics (PK) of clonidine in intensive care unit (ICU) patients in order to develop a dosing regimen for sedation....
3.
van Berlo-van de Laar I, Arbouw M, Bles C
Ned Tijdschr Geneeskd
. 2015 Jul;
159:A8877.
PMID: 26173662
Background: Acute strychnine poisoning is an uncommon form of intoxication, characterized by severe tonic clonic seizures and tetanus-like contractions while the patient is fully conscious. It can result in respiratory...
4.
Arbouw M, Movig K, Guchelaar H, Neef C, Egberts T
Eur J Clin Pharmacol
. 2011 Jul;
68(1):83-8.
PMID: 21779969
Background: It has been suggested that ergoline dopamine agonists can cause ischemic complications. The effect of dopamine agonists in general on the prevalence of ischemic events in patients with Parkinson's...
5.
Arbouw M, Movig K, Egberts T, Poels P, van Vugt J, Wessels J, et al.
Eur J Clin Pharmacol
. 2009 Aug;
65(12):1245-51.
PMID: 19669131
Objective: To identify determinants for the discontinuation of non-ergoline dopamine agonist (DA) treatment in patients with Parkinson’s disease (PD) and to identify genetic determinants in genes encoding dopamine receptor (DR)D2...
6.
Arbouw M, Movig K, Guchelaar H, Poels P, van Vugt J, Neef C, et al.
Eur J Clin Pharmacol
. 2008 Jul;
64(10):1021-6.
PMID: 18626634
Objective: To compare characteristics and incidence of discontinuation of Parkinson's disease (PD) patients starting ropinirole or pramipexole in clinical practice with data from randomised controlled clinical trials (RCTs). Methods: Included...
7.
Arbouw M, van Vugt J, Egberts T, Guchelaar H
Pharmacogenomics
. 2007 Feb;
8(2):159-76.
PMID: 17286539
Pharmacotherapy is the mainstay in the treatment of Parkinson's disease and the armamentarium of drugs available for the therapy of this disease is still expanding. Anti-Parkinson's disease drugs are effective...
8.
Arbouw M, Movig K, Neef C, Guchelaar H, Egberts T
Eur J Clin Pharmacol
. 2007 Jan;
63(2):181-7.
PMID: 17200834
Objective: To assess whether there is an association between initial use of serotonergic antidepressants and changes in antiparkinsonian drug treatment. Methods: A retrospective cohort study was performed with the PHARMO...